Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.

S, Verma; CD, Mazer; AT, Yan; T, Mason; V, Garg; H, Teoh; F, Zuo; A, Quan; ME, Farkouh; DH, Fitchett; SG, Goodman; RM, Goldenberg; RM, Goldenberg; M, Al-Omran; RE, Gilbert; DL, Bhatt; LA, Leiter; P, Jüni; B, Zinman; KA, Connelly

doi:10.1161/circulationaha.119.042375

Public

Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.

Shared by NobleBlocks on Aug 22, 2019 • 12:00 AM UTC

Authors:

Verma S

Mazer CD

Yan AT

Abstract

<h4>Background</h4>SGLT2 (sodium-glucose cotransporter 2) inhibitors lower cardiovascular events in type 2 diabetes mellitus but whether they promote direct cardiac effects remains unknown. We sought to determine if empagliflozin causes a decrease in left ventricular (LV) mass in people with type 2 ...

Subject

Diabetes mellitus

ventricular myocardium

coronary artery disease

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!